Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months ended December 31, 2010
Currency: Indian Rupees (INR) with U.S. Dollar (USD) convenience translation (Rate: 44.80 INR = 1 USD)
Business Overview: DRL is a leading India-based pharmaceutical company operating in Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Principal operations are in India, with significant marketing and manufacturing presence in the U.S., Europe, Russia, and other emerging markets.
Key Financial Metrics
Amounts in millions, unless otherwise noted.
| Metric | 9 Months Ended Dec 31, 2010 (INR) | 9 Months Ended Dec 31, 2010 (USD) | 3 Months Ended Dec 31, 2010 (INR) | 3 Months Ended Dec 31, 2010 (USD) |
|---|---|---|---|---|
| Revenues | 54,520 | 1,217 | 18,985 | 424 |
| Gross Profit | 29,314 | 654 | 10,414 | 232 |
| Gross Margin | 53.8% | 53.8% | 54.9% | 54.9% |
| Net Profit (Loss) | 7,695 | 172 | 2,732 | 61 |
| Operating Cash Flow | 7,184 | 160 | N/A | N/A |
| Short-term Borrowings | 13,563 | 303 | 13,563 | 303 |
| Long-term Borrowings | 233 | 5 | 233 | 5 |
| Cash & Equivalents | 4,126 | 92 | 4,126 | 92 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 1.2% for the nine months ended Dec 31, 2010 (INR 54,520 vs. 53,854) and 9.8% for the quarter (INR 18,985 vs. 17,296). Growth was driven by the Global Generics segment, particularly in North America (+60% QoQ) and India (+14% QoQ), offset by declines in Germany (-33% QoQ) due to price erosion from competitive bidding.
- Profitability Turnaround: The company reported a net profit of INR 7,695 million for the nine months ended Dec 31, 2010, compared to a net loss of INR 597 million in the prior year period. The prior year loss was significantly impacted by impairment charges of INR 8,603 million (goodwill and intangibles) related to the German subsidiary (betapharm). No such impairments occurred in the current period.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 17% quarter-over-quarter, driven by higher legal costs (fexofenadine litigation) and increased sales force/marketing costs in India and Russia. R&D expenses increased 46% quarter-over-quarter due to scale-up in Global Generics and Proprietary Products.
- Debt Structure: Short-term borrowings increased significantly to INR 13,563 million (from INR 5,565 million at March 31, 2010) to fund working capital and capital expenditures. Long-term borrowings decreased to INR 233 million as the company repaid significant foreign currency loans.
Guidance, Outlook, Risks, and Unusual Items
- Guidance: The filing does not provide specific numerical financial guidance for the full fiscal year. Management notes continued focus on capacity expansion and new product launches.
- Recent Developments:
- Bonus Debentures: Received all necessary regulatory approvals (RBI and Income Tax authorities) in early 2011 to issue bonus debentures to shareholders.
- Acquisitions: Agreed to acquire GSK's oral penicillin facility in the U.S. and certain product portfolios (expected closing before June 30, 2011). Acquired non-controlling interests in Australian and South African subsidiaries.
- Asset Sale: Sold marketing authorizations and dossiers for Brazilian products to GSK Brazil for a total consideration of INR 604 million (USD 13 million), with upfront and milestone payments.
- Key Risks and Contingencies:
- Patent Litigation: Ongoing U.S. litigation regarding Fexofenadine (Allegra-D 24). A preliminary injunction issued in June 2010 was dissolved in January 2011, allowing sales to resume, though the case remains pending appeal. Sales are at risk if the plaintiff prevails on appeal.
- German Market: Continued price pressure and competitive bidding in Germany affecting margins. Significant impairment charges were taken in the prior year; no new restructuring charges were recorded in the current period.
- Regulatory: Exposure to the U.S. Patient Protection and Affordable Care Act (PPACA) annual fee on branded/authorized generic sales starting in 2011. Impact on net income is currently unquantified.
- Environmental/Legal: Pending environmental litigation in India regarding effluent discharge (liability considered remote) and indirect tax disputes in India.
Investor Verification Checklist
- Fexofenadine Litigation Outcome: Verify the status of the appeal regarding the dissolved preliminary injunction in the U.S. and potential exposure to damages.
- German Subsidiary Performance: Monitor the impact of competitive bidding tenders on the betapharm subsidiary's revenue and margins in the coming quarters.
- Debt Servicing: Review the sustainability of the increased short-term borrowings (INR 13.5 billion) and the company's ability to service this debt given the reduction in long-term debt.
- PPACA Fee Impact: Assess the potential financial impact of the new U.S. healthcare reform fees on future net income once market share data is finalized.
- Capital Expenditures: Confirm the progress and ROI of the new U.S. manufacturing facility acquisition and other capacity expansion projects funded by recent cash outflows.